EBITDA: Income before interest, taxes, depreciation and amortization.
Recursion Pharmaceuticals, Inc. (RXRX) had EBITDA of $-116.80M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$7.67M |
|
$-131.00M |
|
$11.49M |
|
$-3.82M |
|
$142.64M |
|
$-134.97M |
|
$3.96M |
|
$-131.01M |
|
$-131.01M |
|
$-131.01M |
|
$-131.01M |
|
$-131.00M |
|
$-131.01M |
|
$-134.97M |
|
|
EBITDA |
$-116.80M |
532.46M |
|
532.46M |
|
$-0.25 |
|
$-0.25 |
|
| Balance Sheet Financials | |
$603.46M |
|
$89.62M |
|
$609.21M |
|
$1.21B |
|
$119.89M |
|
$4.75M |
|
$177.78M |
|
$297.67M |
|
$915.00M |
|
$471.76M |
|
$915.00M |
|
534.12M |
|
| Cash Flow Statement Financials | |
$-187.05M |
|
$-2.30M |
|
$-4.74M |
|
$753.92M |
|
$556.82M |
|
$-197.10M |
|
$41.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.03 |
|
-- |
|
-- |
|
0.01 |
|
0.02 |
|
-49.82% |
|
-1759.69% |
|
-1759.69% |
|
-- |
|
-1708.03% |
|
-1708.02% |
|
$-187.35M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
0.53 |
|
168.89 |
|
-14.32% |
|
-27.77% |
|
-10.80% |
|
-14.24% |
|
$1.71 |
|
$-0.35 |
|
$-0.35 |
|